In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
Rhythm Biosciences closer to cancer detection breakthrough
2 minute read
Rhythm Biosciences (ASX:RHY) has provided an important update on its reagent development program.
The program is of significant importance to the company’s ColoSTATTM antibody-based blood test for the early detection of colorectal cancer.
RHY has indicated that the program has showcased positive progress to date and remains on schedule.
Under a research contract with the CSIRO, five mixed monoclonal antibody preparations have passed two out of three preliminary screening tests with the final stage of screening now in progress.
Completion of these tests triggers cloning of the cells required to produce antibodies of interest for ColoSTATTM . Additional tests will be performed to identify which antibodies are best suited to the diagnostic purpose of ColoSTATTM.
Once these are identified, the antibody-producing cell lines will join those already in hand for the two target biomarkers Rhythm has secured. This will lead to the optimisation of antibody production and purification at a laboratory scale, which will support the development of scalable antibody protocols for production of these reagents by a contract manufacturer.
As always, it should be noted that RHY is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
ColoSTATTM uses antibodies to measure the levels of several proteins in the blood. The concentrations of these proteins in blood have been shown to vary in the presence or absence of colorectal cancer.
RHY Managing Director Trevor Lockett spoke on the development.
“Rhythm’s objective in the coming months is to develop our own antibodies and target proteins to give us control of the supply, quality and cost of these key reagents.
“The positive progress to date is essential in underpinning the reliable manufacture of test kits with consistently high diagnostic performance properties, and the results we have achieved in pursuit of this to date have been very pleasing.”